Polyphenon Pharma Receives Orphan Drug Designation For Its Botanical Drug, Polyphenon E, For The Treatment Of CLL
Polyphenon Pharma, an emerging
enquire-based pharmaceutical company, announced that the Food and
Treatment Administration (FDA) has granted Orphan Drug Designation to its
botanical drug, Polyphenon E(R), for the treatment of chronic lymphocytic
leukemia (CLL). A Inject II study is currently underway at the Mayo Clinic
in Rochester, Minnesota where researchers are studying the effects of an
enunciated daily dose of Polyphenon [...]
